http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2638971-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81ad53b64eb74859acdc01278829b080 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2013-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc297b7d411ca1abcbdb64ea5a171ba7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99288171296aef0574f4d354b224a373 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a14c1ebc0de634f8ad487e9e31c90a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be398b02f590028aa883a83be47b3d58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66cc87061487cab00ae1de196919a322 |
| publicationDate | 2017-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2638971-T3 |
| titleOfInvention | Methods to predict and monitor mucosal healing |
| abstract | A method for predicting the likelihood of mucosal healing in a subject who has or is suspected of having an inflammatory bowel disease (IBD), the method comprising: (a) measuring a first set of markers to form a phase marker score inflammatory in which the first set of markers comprises one or more of TWEAK, CRP, ICAM, SAA, VCAM, IL-2, IL-8, IL-12p70, IL-1ß, GMCSF, IFN, IL-6, TNF, ASCA-A, ASCA-G, CBir1, FLA2, FlaX, OmpC, and an anti-drug antibody (ADA) and in which each of the first set of markers is assigned a value based on the concentration or level of the marker relative to a pattern or set of patterns or based on a quantile level of the marker; (b) measure a second set of markers to form a proliferation phase marker score in which the second set of markers comprises one or more of AREG, EREG, HBEGF, HGF, HRGB, BTC, EGF, TGFA, FGF1, FGF2, FGF4, FGF7, FGF9, FGF19, SCF, PDGFA, PDGFB, PDGFC, VEGFA, VEGFB, VEGFC, VEGFD, TGFB1, IL-10 and an anti-TNFα antibody and in which each of the second set of markers is assigns a value based on the concentration or level of the marker relative to a pattern or set of patterns or based on a quantile level of the marker; (c) compare the inflammatory phase marker score with the proliferation phase marker score; and (d) predict the likelihood of mucosal healing based on the comparison in step (c). |
| priorityDate | 2012-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1009.